JUN 26, 2020 1:10 PM PDT

Combining Treatments to Improve Acute Myeloid Leukemia Therapy

WRITTEN BY: Jasper Cantrell

Acute myeloid leukemia (AML) is a type of blood cancer that prevents the complete maturation of stem cells. These immature stem cells accumulate in the blood and interfere with healthy blood cells. AML, being a complex disease with many different sub-types, is notably a challenge to treat. Five-year survival rates are as low as 30%. 

One of the more common subtypes of AML is characterized by the FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (FLT3-ITD) mutation. Essentially there is an extra FLT3 gene where there shouldn’t be. FLT3 is a critical player in the differentiation of stem cells into mature cells, and too much of it in the cell can lead to runaway proliferation and cancer transformation.

FLT3 tyrosine kinase inhibitors (TKI) are a class of cancer drugs that specifically target FLT3. Gilteritinib is a new TKI with fewer side effects than other FLT3 TKIs, though it only has mild anti-cancer effects. Another FLT3-TKI, sorafenib, has had success in combination with the clinical drug arsenic trioxide (ATO).  A team from the School of Medicine at Shanghai Jiao Tong University in China hypothesized that combining gilteritinib with ATO could result in a synergistic similar anti-cancer effect.

Beginning with in vitro cell assays, they found that gilteritinib, in combination with ATO, worked better at reducing cell proliferation, invasion, and increasing cell death by apoptosis than either alone in FLT3-ITD cell lines. Further investigation showed that FLT3 was not the source of the synergy between the two drugs, but genes involved in endoplasmic reticulum stress were. One gene, IRE1a, has a role in a cell death pathway called apoptosis. Gilteritinib suppressed IRE1a expression, but cotreatment with ATO rescued IRE1a expression and induced cell death in cancer cells. The synergistic anti-cancer activity was confirmed in a mouse model, which showed combination therapy could reduce tumor growth better than either drug alone.

Other studies have similarly found that the addition of ATO to an FLT3-TKI could improve a treatment’s anti-cancer effects. Gilterinitib is a second-generation FLT3-TKI, with far fewer side effects seen from other FLT3-TKIs. The team found that combining gilteritinib with ATO, or possibly any drug that induced endoplasmic reticulum stress, could result in a far better therapy than either alone. The group concluded, “Our findings may provide a new target for combination treatment and a novel theoretical basis for the treatment of FLT3-ITD positive AML patients.”

Sources: Cancer Cell International, OncLiveTV

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
MAY 03, 2020
Cancer
New genes targeted for anti-cancer therapies
MAY 03, 2020
New genes targeted for anti-cancer therapies
Research published in the journal Genome Biology reports the discovery of two overlooked genes that have the potential t ...
JUN 15, 2020
Cancer
Using miRNA to Treat Cancer Stem Cells
JUN 15, 2020
Using miRNA to Treat Cancer Stem Cells
In many cancers, there exists a type of cancer cell called a cancer stem cell.  These are cells that, after chemoth ...
JUN 22, 2020
Cancer
Methylation Markers That Can be Used to Diagnose Pancreatic Cancer
JUN 22, 2020
Methylation Markers That Can be Used to Diagnose Pancreatic Cancer
Diagnostic tests are the unsung heroes of cancer treatment. While there are more treatments for cancer coming out every ...
JUL 08, 2020
Drug Discovery & Development
Common Blood Pressure Drugs May Prevent Colon Cancer
JUL 08, 2020
Common Blood Pressure Drugs May Prevent Colon Cancer
Colon cancer is the third most common cancer and the second leading cause of death by cancer around the world. Now, rese ...
JUL 04, 2020
Cancer
New mechanism that supports the progression and relapse cancer discovered
JUL 04, 2020
New mechanism that supports the progression and relapse cancer discovered
Researchers have found a mechanism of a key protein that supports the progression and relapse of cancer. This discovery ...
JUL 13, 2020
Cancer
Breast cancer patients are 60% more likely to die of cancer after surviving a heart attack
JUL 13, 2020
Breast cancer patients are 60% more likely to die of cancer after surviving a heart attack
Unwelcome news from researchers at NYU Grossman School of Medicine suggests that breast cancer patients are 60% more lik ...
Loading Comments...